Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 1.058 billion yuan in 2025, representing a year-on-year growth of 21.80%, and a net profit attributable to shareholders of 236.92 million yuan, up 33.87% year-on-year [4][7] - The growth is driven by the steady sales of core products such as "复瑞彤" and "波开清", as well as the successful launch of new products like "卡格列净片" and "恩格列净片" [7] - The company maintains a dual strategy of generic and innovative drug development, with a projected R&D expenditure of 120 million yuan in 2025, a 2.83% increase year-on-year [7] - The financial structure remains robust, with total equity attributable to shareholders increasing by 18.17% year-on-year, despite a decrease in net asset per share due to a stock dividend expansion [7] Financial Forecast - The company’s total revenue is projected to be 1.058 billion yuan in 2025, with growth rates of 21.80%, 14.57%, and 20.00% for the years 2025, 2026, and 2027 respectively [6][7] - The net profit attributable to shareholders is expected to be 236.92 million yuan in 2025, with growth rates of 33.87%, 12.06%, and 17.49% for the years 2025, 2026, and 2027 respectively [6][7] - The current market valuation corresponds to a price-to-earnings ratio (P/E) of 17.19 for 2025, 15.34 for 2026, and 13.06 for 2027 [7][8]
德源药业（920735）：2025年业绩点评：核心产品稳健增长，DYX116等创新管线稳步推进